AstraZeneca PLC — Board/Management Information 2017

Aug 16, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0963O

AstraZeneca PLC

16 August 2017

16 August 2017 07:00 BST

ASTRAZENECA NON-EXECUTIVE DIRECTOR RETIREMENT

AstraZeneca announced that, on 31 August 2017, Bruce Burlington will retire as a Non-Executive Director of AstraZeneca PLC and as a member of the Audit Committee, the Nomination and Governance Committee, and from his role as Chairman of the Science Committee.

Dr Burlington joined the Board in 2010 and will have served for seven years when he steps down.

Leif Johansson, Chairman of AstraZeneca, said: "Bruce has been an exemplary Director who has made a significant contribution to the Board's work over many years. We have valued his insightful and frank participation as a Board member, and Chairman of the Science Committee during a period of innovation-led transformation at AstraZeneca. His diligence and commitment to the work of the Audit Committee and the Nomination and Governance Committee should also be acknowledged. On behalf of all Board members, we will miss Bruce as a colleague and send him our very best wishes for the future."

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Esra Erkal-Paler	UK/Global	+44 203 749 5638
Karen Birmingham	UK/Global	+44 203 749 5634
Rob Skelding	UK/Global	+44 203 749 5821
Matt Kent	UK/Global	+44 203 749 5906
Jacob Lund	Sweden	+46 8 553 260 20
Michele Meixell	US	+1 302 885 2677
Investor Relations
Thomas Kudsk Larsen		+44 203 749 5712
Craig Marks	Finance, Fixed Income, M&A	+44 7881 615 764
Henry Wheeler	Oncology	+44 203 749 5797
Mitchell Chan	Oncology	+1 240 477 3771
Nick Stone	Respiratory, Brilinta	+44 203 749 5716
Christer Gruvris	Diabetes; Autoimmunity, Neuroscience & Infection	+44 203 749 5711
US toll free		+1 866 381 7277

Adrian Kemp

Company Secretary, AstraZeneca PLC

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOASFSESIFWSESA